OliX Pharmaceuticals올릭스

OliX's revenue is small against heavy operating losses, and recent clinical and management news has pushed the shares down sharply.

OliX Pharmaceuticals is an oligonucleotide drug developer that earns most of its revenue from out-licensing its RNAi platform and drug candidates to partners such as Hansoh in China and Eli Lilly in the US. As of H1 2026 trailing figures, revenue was about ₩13.6B against an operating loss of about ₩41.6B, and the company holds about ₩111.5B in cash against ₩19.6B in borrowings. The share price closed at ₩96,100 on 2026-10-26, well below its 52-week high of ₩217,000.

What stands out

• Trailing revenue of about ₩13.6B is far below operating losses of about ₩41.6B, giving an operating margin of roughly -305%.
• Free cash flow over the trailing period was about -₩30.1B, and the company does not pay a dividend.
• The 2025 annual revenue of about ₩14.7B was up 158% on 2024, but 2025 operating loss was still about ₩30.0B.
• Recent news centres on a rejected clinical trial application and an unclear technology transfer outcome tied to the Peptron matter, and the shares fell 14% on 2026-10-14.
• Over the last 20 days, foreign and retail investors were net sellers while institutions were net buyers; foreign ownership rose from 7.8% to 9.8% over 60 days.

What to watch

• Any update on the rejected clinical trial application and on the technology transfer status, as reported in news and filings.
• Further filings on major management matters and the ongoing amended disclosures in September and October 2026.
• Cash runway: the data shows ₩111.5B in cash against continuing operating losses, so future filings on funding or licensing deals would matter.